FALLS CHURCH, Va., July 23, 2019 /PRNewswire-PRWeb/ -- "For too long it's been virtually impossible for Americans to know the real price and quality of healthcare services and the services they receive. With today's historic action, we are fundamentally changing the nature of the healthcare marketplace. This is bigger than anything we've done in this particular realm."
—HHS Secretary Alex Azar
The drug pricing and reimbursement landscape is changing dramatically. From President Trump's June 24, 2019 executive order requiring healthcare providers to tell patients their out-of-pocket costs prior to receiving services, the May 2019 final rule requiring drug pricing in television ads, recent DOJ enforcement actions, to CMS rules for Medicare Part D and drug pricing bills working through Congressional committees.
Understanding the current policies — and proposed changes — and how to apply them to product development and commercialization plans will greatly impact the success of an organizations products.
Nationally recognized FDA regulatory and life sciences attorney Bethany Hills-Grois, a partner with Morrison & Foerster, is here to help and explain:
Interested in registering multiple sites? Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.
Webinar Details: Drug Pricing and Reimbursement Navigating the Changes, Anticipating the Future **An FDAnews Webinar** Tuesday, August 6, 2019 • 1:30-3:00 p.m. EDT https://www.fdanews.com/drugpricingandreimbursement
Tuition: $287 per site
Easy Ways to Register: Online: https://www.fdanews.com/drugpricingandreimbursement By phone: 888-838-5578 or 703-538-7600
About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.
SOURCE FDAnews
Advertisement
—HHS Secretary Alex Azar
The drug pricing and reimbursement landscape is changing dramatically. From President Trump's June 24, 2019 executive order requiring healthcare providers to tell patients their out-of-pocket costs prior to receiving services, the May 2019 final rule requiring drug pricing in television ads, recent DOJ enforcement actions, to CMS rules for Medicare Part D and drug pricing bills working through Congressional committees.
Advertisement
Understanding the current policies — and proposed changes — and how to apply them to product development and commercialization plans will greatly impact the success of an organizations products.
Nationally recognized FDA regulatory and life sciences attorney Bethany Hills-Grois, a partner with Morrison & Foerster, is here to help and explain:
- How drug pricing policies may impact labeling and promotional activity, such as TV ads
- Practical tips on product data development to align with drug pricing policies
- The drug pricing and reimbursement framework, including the roles FDA, CMS and private parties play
- Drug pricing proposals being considered in Congress… and which ones are likely to pass before the November elections
Interested in registering multiple sites? Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.
Webinar Details: Drug Pricing and Reimbursement Navigating the Changes, Anticipating the Future **An FDAnews Webinar** Tuesday, August 6, 2019 • 1:30-3:00 p.m. EDT https://www.fdanews.com/drugpricingandreimbursement
Tuition: $287 per site
Easy Ways to Register: Online: https://www.fdanews.com/drugpricingandreimbursement By phone: 888-838-5578 or 703-538-7600
About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.
SOURCE FDAnews
